Weidinger, Stephan
Beck, Lisa A.
Bieber, Thomas
Kabashima, Kenji
Irvine, Alan D.
Article History
First Online: 21 June 2018
Competing interests
: S.W. has received honoraria for invited lectures from and served on advisory boards for Galderma, Novartis, Pfizer, Regeneron and Sanofi and has received research funding from La Roche-Posay, Novartis, Pfizer and Sanofi. L.A.B. has received consulting fees from AbbVie, AnaptysBio, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Lilly, Novan, Novartis, Realm Therapeutics, Regeneron and Sanofi-Genzyme; she is principal investigator for clinical trials for AbbVie, Realm Therapeutics and Regeneron and is a stock owner of Medtronic and Pfizer. T.B. has received honoraria for invited lectures from and served on consultant and/or advisory boards for AbbVie, Allmiral, AnaptysBio, Asana Biosciences, Celgene, Daiichi-Sankyo, Dermavant, Galapagos, Galderma, Glenmark, GlaxoSmithKline, Kymab, LEO Pharma, La Roche-Posay, Lilly, L’Oréal, Menlo, Novartis, Pfizer, Roche–Genentech and Sanofi-Genzyme; he was principal investigator for clinical trials with Galderma, LEO Pharma, Lilly, Menlo, Pfizer, Regeneron–Sanofi and Roche–Genentech. K.K. has received honoraria for invited lectures from and served on consultant and/or advisory boards for Chugai, Kyowa Hakko Kirin, LEO Pharma, Mitsubishi Tanabe, Maruho, Pola and Regeneron–Sanof; he was principal investigator for clinical trials with Japan Tobacco, Maruho and Regeneron–Sanofi. A.D.I. has received honoraria for invited lectures from and served on consultant and/or advisory boards for AbbVie, Galderma, Lilly, Novartis, Pfizer, Roche–Genentech and Sanofi-Genzyme; he was principal investigator for clinical trials with AbbVie and Regeneron–Sanofi.